SGCIA
EGRX
Smith Graham & Co Investment Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-273,099
| Closed | -$4.31M | – | 144 |
|
|
2023
Q3 | $4.31M | Buy |
273,099
+3,648
| +1% | +$57.5K | 0.54% | 93 |
|
|
2023
Q2 | $5.24M | Buy |
269,451
+32,568
| +14% | +$633K | 0.63% | 69 |
|
|
2023
Q1 | $6.72M | Buy |
236,883
+5,661
| +2% | +$161K | 0.82% | 49 |
|
|
2022
Q4 | $6.76M | Sell |
231,222
-799
| -0.3% | -$23.4K | 0.83% | 44 |
|
|
2022
Q3 | $6.13M | Sell |
232,021
-322
| -0.1% | -$8.51K | 0.82% | 46 |
|
|
2022
Q2 | $10.3M | Sell |
232,343
-2,377
| -1% | -$106K | 1.27% | 9 |
|
|
2022
Q1 | $11.6M | Sell |
234,720
-1,531
| -0.6% | -$75.8K | 1.21% | 14 |
|
|
2021
Q4 | $12M | Sell |
236,251
-19,281
| -8% | -$982K | 1.2% | 16 |
|
|
2021
Q3 | $14.3M | Sell |
255,532
-22,040
| -8% | -$1.23M | 1.43% | 8 |
|
|
2021
Q2 | $11.9M | Sell |
277,572
-35,145
| -11% | -$1.5M | 1.05% | 24 |
|
|
2021
Q1 | $13.1M | Buy |
312,717
+128,293
| +70% | +$5.36M | 1.06% | 21 |
|
|
2020
Q4 | $8.59M | Sell |
184,424
-3,374
| -2% | -$157K | 0.79% | 47 |
|
|
2020
Q3 | $7.98M | Buy |
187,798
+29,127
| +18% | +$1.24M | 0.91% | 32 |
|
|
2020
Q2 | $7.61M | Buy |
158,671
+7,628
| +5% | +$366K | 0.92% | 37 |
|
|
2020
Q1 | $6.95M | Buy |
151,043
+11,029
| +8% | +$507K | 1.08% | 23 |
|
|
2019
Q4 | $8.41M | Sell |
140,014
-14,640
| -9% | -$880K | 0.82% | 48 |
|
|
2019
Q3 | $8.75M | Buy |
154,654
+980
| +0.6% | +$55.4K | 0.93% | 28 |
|
|
2019
Q2 | $8.56M | Buy |
153,674
+64,890
| +73% | +$3.61M | 0.92% | 30 |
|
|
2019
Q1 | $4.48M | Buy |
+88,784
| New | +$4.48M | 0.49% | 121 |
|